BEAM
Price
$27.47
Change
-$0.67 (-2.38%)
Updated
Dec 26, 02:09 PM (EDT)
Capitalization
2.86B
67 days until earnings call
Intraday BUY SELL Signals
CRSP
Price
$55.21
Change
-$1.50 (-2.65%)
Updated
Dec 26, 02:43 PM (EDT)
Capitalization
5.4B
53 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs CRSP

Header iconBEAM vs CRSP Comparison
Open Charts BEAM vs CRSPBanner chart's image
Beam Therapeutics
Price$27.47
Change-$0.67 (-2.38%)
Volume$118
Capitalization2.86B
CRISPR Therapeutics AG
Price$55.21
Change-$1.50 (-2.65%)
Volume$670
Capitalization5.4B
BEAM vs CRSP Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. CRSP commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Buy and CRSP is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (BEAM: $28.14 vs. CRSP: $56.71)
Brand notoriety: BEAM and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 20% vs. CRSP: 30%
Market capitalization -- BEAM: $2.86B vs. CRSP: $5.4B
BEAM [@Biotechnology] is valued at $2.86B. CRSP’s [@Biotechnology] market capitalization is $5.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, BEAM is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 5 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 5 bullish, 5 bearish.
  • CRSP’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both BEAM and CRSP are a good buy in the short-term.

Price Growth

BEAM (@Biotechnology) experienced а +9.92% price change this week, while CRSP (@Biotechnology) price change was +3.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

CRSP is expected to report earnings on Feb 17, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.4B) has a higher market cap than BEAM($2.86B). CRSP YTD gains are higher at: 44.080 vs. BEAM (13.468). BEAM has higher annual earnings (EBITDA): -434.55M vs. CRSP (-555.73M). CRSP has more cash in the bank: 1.92B vs. BEAM (1.08B). BEAM has less debt than CRSP: BEAM (151M) vs CRSP (211M). BEAM has higher revenues than CRSP: BEAM (55.7M) vs CRSP (35M).
BEAMCRSPBEAM / CRSP
Capitalization2.86B5.4B53%
EBITDA-434.55M-555.73M78%
Gain YTD13.46844.08031%
P/E RatioN/AN/A-
Revenue55.7M35M159%
Total Cash1.08B1.92B56%
Total Debt151M211M72%
FUNDAMENTALS RATINGS
BEAM vs CRSP: Fundamental Ratings
BEAM
CRSP
OUTLOOK RATING
1..100
2622
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
4046
P/E GROWTH RATING
1..100
10078
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (33) in the null industry is somewhat better than the same rating for CRSP (72) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than CRSP’s over the last 12 months.

BEAM's Profit vs Risk Rating (100) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that BEAM’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (96) in the Biotechnology industry is in the same range as BEAM (97) in the null industry. This means that CRSP’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's Price Growth Rating (40) in the null industry is in the same range as CRSP (46) in the Biotechnology industry. This means that BEAM’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (78) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that CRSP’s stock grew similarly to BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMCRSP
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 10 days ago
85%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
87%
Aroon
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
CRSP
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSCNX24.090.07
+0.29%
Loomis Sayles Small Cap Value N
FGKFX39.050.08
+0.21%
Fidelity Growth Company K6
TADCX26.140.05
+0.19%
Transamerica US Growth C
DHPIX16.33N/A
N/A
Diamond Hill Mid Cap I
DNLAX47.44-0.10
-0.21%
BNY Mellon Natural Resources A

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+1.33%
CRSP - BEAM
71%
Closely correlated
+0.44%
RXRX - BEAM
61%
Loosely correlated
+0.92%
NTLA - BEAM
61%
Loosely correlated
+1.80%
PRME - BEAM
59%
Loosely correlated
-3.25%
AXON - BEAM
57%
Loosely correlated
+0.02%
More

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+0.44%
BEAM - CRSP
71%
Closely correlated
+1.33%
RXRX - CRSP
67%
Closely correlated
+0.92%
ABSI - CRSP
61%
Loosely correlated
+1.14%
NTLA - CRSP
60%
Loosely correlated
+1.80%
PRME - CRSP
60%
Loosely correlated
-3.25%
More